Form 4: Erasca Director Michael Varney Granted 120,000 Stock Options

Erasca, Inc. Director Michael David Varney was granted 120,000 stock options with an exercise price of $1.45, vesting fully on June 24, 2026.

Summary

• Michael David Varney, a Director of Erasca, Inc. (ERAS), acquired 120,000 stock options on June 24, 2025.
• The stock options have an exercise price of $1.45 per share.
• These options are scheduled to vest 100% on June 24, 2026, contingent upon Mr. Varney's continuous service to the Issuer.
• The expiration date for these stock options is June 23, 2035.
• Following this transaction, Mr. Varney beneficially owns 120,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal for aligning management interests with shareholder value, although it is a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of 120,000 stock options to Director Michael David Varney aligns his interests with shareholders, incentivizing long-term performance and value creation.
• The options have a long expiration date of June 23, 2035, providing ample time for potential appreciation and value realization.

Risks

• The value of the stock options is contingent on the future performance of Erasca, Inc.'s common stock, and there is no guarantee that the stock price will exceed the exercise price of $1.45.
• The vesting of the options is subject to the reporting person's continuous service to the Issuer until June 24, 2026, meaning the options could be forfeited if service ceases before this date.

Future Outlook

The grant of stock options with a future vesting date implies an expectation of continued service from the director and potential future value creation for the company's stock, aligning long-term incentives.

Industry Context

This Form 4 filing reflects a standard practice of granting equity compensation to directors to align their interests with shareholders, a common corporate governance practice across publicly traded companies, particularly prevalent in the biotechnology and pharmaceutical industries to incentivize long-term commitment and performance.

Comparison to Industry Standards

• The grant of stock options to directors is a common form of equity compensation in publicly traded companies, especially in growth-oriented sectors like biotechnology, to incentivize long-term commitment and performance.
• The specific terms, such as the exercise price and vesting schedule, would typically be benchmarked against peer companies of similar size and stage within the biotechnology sector, though no specific comparative data or companies are provided in this filing.

Related Party Transactions

• The grant of 120,000 stock options to Michael David Varney, a Director of Erasca, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's interests with shareholders, potentially leading to improved long-term performance and value creation if the stock price appreciates.
• Management/Directors: Michael David Varney receives additional equity compensation, incentivizing his continued service and performance for the company.

Next Steps

• The stock options are scheduled to vest 100% on June 24, 2026, subject to the reporting person's continuous service to the Issuer.

Key Dates

Keywords

Erasca, ERAS, stock options, director, insider transaction, Form 4, equity compensation, Michael David Varney